公开(公告)号：US20230112948A1

公开(公告)日：2023-04-13

申请号：US17967415

申请日：2022-10-17

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P25/00 ,  A61P25/24 ,  A61P25/22

Abstract: This invention provides a method of treating depression or anxiety in a human subject by administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230100072A1

公开(公告)日：2023-03-30

申请号：US17980590

申请日：2022-11-04

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P31/14

Abstract: The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.

公开(公告)号：US20240398778A1

公开(公告)日：2024-12-05

申请号：US18814529

申请日：2024-08-25

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61K9/00 ,  A61P25/14

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US20190350914A1

公开(公告)日：2019-11-21

申请号：US16436947

申请日：2019-06-11

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Aric ORBACH ,  Michael HAYDEN

IPC: A61K31/451 ,  A61P25/16 ,  A61K9/00 ,  A61K45/06 ,  A61P25/14

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.

公开(公告)号：US20230190724A1

公开(公告)日：2023-06-22

申请号：US18172927

申请日：2023-02-22

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61K45/06 ,  A61P25/28

CPC classification number: A61K31/451 ,  A61K45/06 ,  A61P25/28

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.

公开(公告)号：US20230165849A2

公开(公告)日：2023-06-01

申请号：US16952123

申请日：2020-11-19

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61P25/14 ,  A61K9/00

CPC classification number: A61K31/451 ,  A61P25/14 ,  A61K9/0053 ,  A61K9/0019

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US20220193059A1

公开(公告)日：2022-06-23

申请号：US17425951

申请日：2020-02-04

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA ,  Angela CENCI NILSSON

IPC: A61K31/451 ,  A61P25/16

Abstract: The subject invention provides a method for treating Parkinsonism or symptoms thereof by low dose pridopidine.

公开(公告)号：US20210275512A1

公开(公告)日：2021-09-09

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61P25/14 ,  A61K45/06 ,  A61P25/16 ,  A61K9/00

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia

公开(公告)号：US20240197708A1

公开(公告)日：2024-06-20

申请号：US18553758

申请日：2022-04-14

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P25/14 ,  A61P25/28

CPC classification number: A61K31/451 ,  A61P25/14 ,  A61P25/28

Abstract: Disclosed herein are methods treating prodromal HD in a subject, wherein the subject has at least 36 CAG repeats in the huntingtin (Htt) gene, wherein the method comprises administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240148708A1

公开(公告)日：2024-05-09

申请号：US18416210

申请日：2024-01-18

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/4418 ,  A61P25/28

CPC classification number: A61K31/4418 ,  A61P25/28

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.